628 related articles for article (PubMed ID: 33222488)
21. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
Johnson DR; Diehn FE; Giannini C; Jenkins RB; Jenkins SM; Parney IF; Kaufmann TJ
AJNR Am J Neuroradiol; 2017 Apr; 38(4):678-684. PubMed ID: 28126746
[TBL] [Abstract][Full Text] [Related]
22. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
23. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
[TBL] [Abstract][Full Text] [Related]
24. Noninvasive Assessment of
Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
[TBL] [Abstract][Full Text] [Related]
25. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
26. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance imaging texture analyses in lower-grade gliomas with a commercially available software: correlation of apparent diffusion coefficient and T2 skewness with 1p/19q codeletion.
Kanazawa T; Minami Y; Takahashi H; Fujiwara H; Toda M; Jinzaki M; Yoshida K; Sasaki H
Neurosurg Rev; 2020 Aug; 43(4):1211-1219. PubMed ID: 31402410
[TBL] [Abstract][Full Text] [Related]
28. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
[TBL] [Abstract][Full Text] [Related]
29. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
[TBL] [Abstract][Full Text] [Related]
30. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
Reyes-Botero G; Dehais C; Idbaih A; Martin-Duverneuil N; Lahutte M; Carpentier C; Letouzé E; Chinot O; Loiseau H; Honnorat J; Ramirez C; Moyal E; Figarella-Branger D; Ducray F;
Neuro Oncol; 2014 May; 16(5):662-70. PubMed ID: 24353325
[TBL] [Abstract][Full Text] [Related]
31. Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas.
Nishikawa T; Ohka F; Aoki K; Suzuki H; Motomura K; Yamaguchi J; Maeda S; Kibe Y; Shimizu H; Natsume A; Innan H; Saito R
Brain Tumor Pathol; 2023 Apr; 40(2):85-92. PubMed ID: 36991274
[TBL] [Abstract][Full Text] [Related]
32. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.
Latysheva A; Emblem KE; Brandal P; Vik-Mo EO; Pahnke J; Røysland K; Hald JK; Server A
Neuroradiology; 2019 May; 61(5):545-555. PubMed ID: 30712139
[TBL] [Abstract][Full Text] [Related]
33. T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology.
Foltyn M; Nieto Taborda KN; Neuberger U; Brugnara G; Reinhardt A; Stichel D; Heiland S; Herold-Mende C; Unterberg A; Debus J; von Deimling A; Wick W; Bendszus M; Kickingereder P
Neurooncol Adv; 2020; 2(1):vdaa004. PubMed ID: 32642675
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.
Alentorn A; van Thuijl HF; Marie Y; Alshehhi H; Carpentier C; Boisselier B; Laigle-Donadey F; Mokhtari K; Scheinin I; Wesseling P; Ylstra B; Capelle L; Hoang-Xuan K; Sanson M; Delattre JY; Reijneveld JC; Idbaih A
Neuro Oncol; 2014 Mar; 16(3):400-8. PubMed ID: 24335697
[TBL] [Abstract][Full Text] [Related]
35. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
36. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K
Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981
[TBL] [Abstract][Full Text] [Related]
37. The cortical high-flow sign of oligodendroglioma, IDH-mutant and 1p/19q-codeleted: comparison between arterial spin labeling and dynamic susceptibility contrast methods.
Yamashita K; Togao O; Kikuchi K; Kuga D; Sangatsuda Y; Fujioka Y; Yoshimoto K; Ishigami K
Neuroradiology; 2024 Feb; 66(2):187-192. PubMed ID: 38127124
[TBL] [Abstract][Full Text] [Related]
38. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
[TBL] [Abstract][Full Text] [Related]
39. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
40. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
